PharmaEssentia said a second-phase partial ruling in its ICC arbitration with AOP requires AOP to pay more than EUR17 million in goods payments and royalties for 2019 through the first half of 2023, while also ordering PharmaEssentia to refund about EUR31.6 million over a 2019-2021 drug procurement pricing dispute. The company said the tribunal also found compensation liabilities of EUR31,319,250.27 and EUR34,561,864 related to a five-month delay in European drug approval and a 4.5-month delay in product supply. The Taiwan-based company said the outcome has no material impact on its financial condition or business operations, citing 2025 revenue of NT$15.6 billion, revenue of nearly NT$14.5 billion in the first seven months of 2026, and nearly EUR100 million in royalties and payments it says AOP has owed since the second half of 2023. PharmaEssentia said it will seek to set aside parts of the ruling, particularly the pricing calculation, and pushed back on AOP's separate public statement that framed the case as putting PharmaEssentia on the hook for more than EUR100 million plus a further roughly EUR65 million in receivables. The dispute centers on licensing and supply arrangements for Ropeginterferon alfa-2b, marketed as Besremi, in Europe. An ICC first-phase partial ruling issued on February 17, 2025 found PharmaEssentia bore partial liability for delays, and that award is already under review before the German Federal Supreme Court. PharmaEssentia said the latest ruling is also likely to face set-aside proceedings, leaving the years-long arbitration unresolved.